The biopharmaceutical industry’s commercial model has been an important part of each company’s success, but the current capabilities and strategies are unlikely to suffice for future …

Artificial intelligence-enabled technologies are transforming the different parts of the biopharma industry value chain, creating new business opportunities. Explore Deloitte's collection of …

May 6, 2021 · Consumers may appreciate pharma companies’ efforts to speed up the process of bringing COVID-19 vaccines to market. How might biopharma continue to innovate while …

Discover industry insights and audit, tax, and consulting services that drive impact from Deloitte’s global network of member firms.

Inorganic growth activity in life sciences— have we reached the bottom? Our previous report outlined a steep decline in life sciences deal-making in the first half of 2022 from record levels …

Apr 10, 2024 · バイオ・創薬スタートアップは新規モダリティの創出の原動力であり、ひとたび新規モダリティが上市されると、それらは大きな市場を形成し、同時に業界構造についても …

Deloitte US | Audit, Consulting, Advisory, and Tax Services

2024年10月から11月にかけて実施された2025年度版グローバル自動車消費者調査では、次の4つの主要なトレンド取り上げる。 ほとんどの市場でバッテリー式電気自動車（BEV）への関 …

Supply chain-driven innovation, such as novel manufacturing techniques, alternative modes of distribution, supply chain segmentation, and partnerships with third-party service providers …

A potential use of digital twins among biopharma companies is the simulation of clinical trials to include budgets, patient selection, and probability of success.9 Digital twins can form part of a …